| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/05/2023 | 76.13% | Craig-Hallum | → $18 | Initiates Coverage On | → Buy |
| 08/03/2023 | 66.34% | Piper Sandler | $15 → $17 | Maintains | Overweight |
| 07/11/2023 | 56.56% | Citigroup | $14 → $16 | Maintains | Buy |
| 05/03/2023 | 36.99% | Citigroup | $13 → $14 | Maintains | Buy |
| 05/03/2023 | 46.77% | Piper Sandler | $13 → $15 | Maintains | Overweight |
| 05/03/2023 | 36.99% | Morgan Stanley | $11 → $14 | Maintains | Equal-Weight |
| 04/03/2023 | 27.2% | Citigroup | $12 → $13 | Maintains | Buy |
| 02/27/2023 | 46.77% | Wells Fargo | $10 → $15 | Upgrades | Equal-Weight → Overweight |
| 02/24/2023 | 17.42% | Citigroup | $10 → $12 | Maintains | Buy |
| 02/23/2023 | 95.69% | Canaccord Genuity | $18 → $20 | Maintains | Buy |
| 02/23/2023 | 7.63% | Morgan Stanley | $9.5 → $11 | Maintains | Equal-Weight |
| 01/06/2023 | -7.05% | Morgan Stanley | $14 → $9.5 | Maintains | Equal-Weight |
| 01/03/2023 | -21.72% | B of A Securities | → $8 | Downgrades | Neutral → Underperform |
| 12/12/2022 | -41.29% | Wells Fargo | $13.5 → $6 | Maintains | Equal-Weight |
| 12/12/2022 | -2.15% | Citigroup | $14 → $10 | Upgrades | Neutral → Buy |
| 11/07/2022 | 36.99% | Morgan Stanley | $19 → $14 | Maintains | Equal-Weight |
| 11/04/2022 | 27.2% | Piper Sandler | $25 → $13 | Maintains | Overweight |
| 10/11/2022 | 85.91% | Morgan Stanley | $21 → $19 | Maintains | Equal-Weight |
| 08/04/2022 | 105.48% | Morgan Stanley | $19 → $21 | Maintains | Equal-Weight |
| 08/03/2022 | 144.62% | Piper Sandler | $37 → $25 | Maintains | Overweight |
| 07/18/2022 | 95.69% | Stifel | $32 → $20 | Maintains | Buy |
| 07/15/2022 | 85.91% | Morgan Stanley | $30 → $19 | Maintains | Equal-Weight |
| 07/11/2022 | 85.91% | Citigroup | $23 → $19 | Downgrades | Buy → Neutral |
| 05/17/2022 | 125.05% | Citigroup | $32 → $23 | Maintains | Buy |
| 02/25/2022 | 193.54% | Morgan Stanley | $37 → $30 | Maintains | Equal-Weight |
| 02/24/2022 | 164.19% | Wells Fargo | $55 → $27 | Maintains | Equal-Weight |
| 01/07/2022 | 262.04% | Morgan Stanley | $48 → $37 | Maintains | Equal-Weight |
| 12/08/2021 | 340.31% | Piper Sandler | → $45 | Upgrades | Neutral → Overweight |
| 11/03/2021 | 438.16% | Wells Fargo | $56 → $55 | Maintains | Equal-Weight |
| 08/04/2021 | 418.59% | Canaccord Genuity | $65 → $53 | Maintains | Buy |
| 04/01/2021 | 487.08% | Citigroup | → $60 | Initiates Coverage On | → Buy |
| 03/25/2021 | 389.24% | Piper Sandler | → $50 | Initiates Coverage On | → Neutral |
| 03/10/2021 | 604.5% | B of A Securities | → $72 | Upgrades | Neutral → Buy |
| 03/03/2021 | 536.01% | Canaccord Genuity | $49 → $65 | Maintains | Buy |
| 03/03/2021 | 418.59% | Morgan Stanley | $52 → $53 | Maintains | Equal-Weight |
| 12/15/2020 | 408.81% | Morgan Stanley | $46 → $52 | Maintains | Equal-Weight |
| 11/11/2020 | 350.1% | Morgan Stanley | $44 → $46 | Maintains | Equal-Weight |
| 10/26/2020 | 389.24% | B of A Securities | → $50 | Initiates Coverage On | → Buy |
| 10/26/2020 | 379.45% | Canaccord Genuity | → $49 | Initiates Coverage On | → Buy |
| 10/26/2020 | 389.24% | Stifel | → $50 | Initiates Coverage On | → Buy |
| 10/26/2020 | 330.53% | Morgan Stanley | → $44 | Initiates Coverage On | → Equal-Weight |
| 10/26/2020 | 350.1% | Wells Fargo | → $46 | Initiates Coverage On | → Equal-Weight |
What is the target price for Pulmonx (LUNG)?
The latest price target for Pulmonx (NASDAQ: LUNG) was reported by Craig-Hallum on September 5, 2023. The analyst firm set a price target for $18.00 expecting LUNG to rise to within 12 months (a possible 76.13% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pulmonx (LUNG)?
The latest analyst rating for Pulmonx (NASDAQ: LUNG) was provided by Craig-Hallum, and Pulmonx initiated their buy rating.
When is the next analyst rating going to be posted or updated for Pulmonx (LUNG)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pulmonx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pulmonx was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.
Is the Analyst Rating Pulmonx (LUNG) correct?
While ratings are subjective and will change, the latest Pulmonx (LUNG) rating was a initiated with a price target of $0.00 to $18.00. The current price Pulmonx (LUNG) is trading at is $10.22, which is within the analyst's predicted range.